Antibody persistence and revaccination recommendations of MenACWY-TT: a review of clinical studies assessing antibody persistence up to 10 years after vaccination-Reference-Cited by-同舟云学术

Antibody persistence and revaccination recommendations of MenACWY-TT: a review of clinical studies assessing antibody persistence up to 10 years after vaccination

Published:2024-06-07 Issue:1 Volume:23 Page:614-635
ISSN:1476-0584
Container-title:Expert Review of Vaccines
language:en
Short-container-title:Expert Review of Vaccines

Author:

Burman Cynthia¹,Knuf Markus²³,Sáfadi Marco Aurelio P.⁴^ORCID,Findlow Jamie⁵

Affiliation:

1. Vaccines, Antivirals and Evidence Generation, Pfizer Inc, Collegeville, PA, USA

2. Children’s Hospital, Worms Clinic, Worms, Germany

3. Pediatric Infectious Diseases, University Medicine Mainz, Mainz, Germany

4. Department of Pediatrics, Santa Casa de São Paulo School of Medical Sciences, São Paulo, Brazil

5. Vaccines, Antivirals and Evidence Generation, Pfizer Ltd, Surrey, UK

Funder

Pfizer

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14760584.2024.2348609

Reference77 articles.

1. Neisseria meningitidis: pathogenesis and immunity

2. Meningococcal serogroups and surveillance: a systematic review and survey

3. Meningococcal disease: Clinical presentation and sequelae

4. Epidemiology of invasive meningococcal disease worldwide from 2010–2019: a literature review

5. Meningococcal Quadrivalent Tetanus Toxoid Conjugate Vaccine (MenACWY-TT; Nimenrix®): A Review

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine Versus Nimenrix in Healthy Adolescents: A Randomized Phase IIIb Multicenter Study;Infectious Diseases and Therapy;2024-07-02